Tango Therapeutics Inc. (TNGX) saw its stock price plummet 10.82% during intraday trading on Thursday, as the biopharmaceutical company faced significant selling pressure.

The sharp decline appears to be primarily driven by a rating change from investment firm Jefferies, which downgraded Tango Therapeutics from "Buy" to "Hold" while simultaneously raising its price target to $27 from $18. This mixed signal—a more cautious investment rating despite a higher valuation estimate—likely prompted investor concerns and triggered the sell-off.

Other analysts maintained positive views on the stock, with Wedbush raising its target price to $33 from $19 and Canaccord Genuity reaffirming its Buy rating with a $30 target. However, the Jefferies downgrade to a neutral stance seems to have outweighed these optimistic assessments in today's trading session.